Belhaven Biopharma

Executive Summary

Belhaven Biopharma is a private, US-based biotechnology company founded in 2018 and headquartered in Durham, North Carolina. The company is focused on addressing the unmet needs in severe allergy management through its innovative needle-free drug delivery platform. Its lead candidate, Nasdepi®, is a dry powder epinephrine nasal spray designed to be a compact, heat-stable, and user-friendly alternative to traditional auto-injectors for the treatment of anaphylaxis. By eliminating the need for needles and overcoming barriers such as needle phobia, device complexity, and temperature instability, Belhaven aims to improve global access to life-saving epinephrine, particularly in out-of-hospital settings. The company’s technology represents a significant advancement in the anaphylaxis treatment landscape, which has long been dominated by auto-injectors that are bulky, expensive, and require careful storage.

Upcoming Catalysts (preview)

• Q2 2026Phase 2/3 clinical trial results for Nasdepi45% success
• Q4 2026FDA pre-NDA meeting or Breakthrough Therapy designation50% success
• H1 2027Strategic partnership or licensing deal with a major pharmaceutical company30% success